Skip to contentG
GT Biopharma, Inc.
G
GTBPGT Biopharma, Inc. Q3 2021 · 10-Q
Revenue$0.00$0.00— vs Q3 2020 Net Income-$5.45M-$5.45MN/M vs Q3 2020 EPS Diluted-$0.17-$0.17N/M vs Q3 2020 Operating Income-$5,954,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
derived
ended Sep 30, 2021 · filed Nov 10, 2021 · 41 d after period end